UNSPSC 51284612: Meropenem anhydrous

This classification denotes a beta-lactam antibiotic with the molecular formula C17H25N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YOP6PX0BAO, chemically known as (4r,5s,6s)-3-(((3s,5s)-5-(dimethylcarbamoyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, but more generally known as meropenem anhydrous, which bears US NIH Compound Identifier 64778.

UNSPSC 51284612 Meropenem anhydrous is a Commodity code for a specific carbapenem antibiotic active pharmaceutical ingredient, but the recent state and local opportunities posted under this code do not involve meropenem procurement. Instead, the two most recent records reflect pharmaceutical supply and drug-response product acquisitions that fall outside the scope of this antibiotic compound — one covers doxycycline and ciprofloxacin tablets through a cooperative purchasing vehicle, and the other addresses naloxone and drug deactivation systems for community health. The mismatch between the code's nominal scope and the actual work being solicited suggests minimal relevant recent activity under this code in state and local procurement. State and local health departments and county public health agencies appear to be the primary buyers when pharmaceutical products are procured, typically through cooperative purchasing arrangements or competitive invitation-for-bid processes.

The two records in the recent-opportunities block do not reflect active solicitations for meropenem. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for doxycycline and ciprofloxacin products totaling $2,999,999.11 over the contract life, but meropenem was not part of the award. Seminole County, Florida issued an IFB (60459723LAS) on June 30, 2026, with a July 26, 2023 response deadline for naloxone and drug deactivation systems — again, outside meropenem's scope. Activity appears concentrated in Florida and Illinois, but the code shows no relevant current demand signal for the meropenem compound itself. Firms pursuing work under this code should verify whether state and local health procurement offices are actively sourcing meropenem independently or through group purchasing organizations before investing business-development resources.